Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Perforin-2 Breaches the Envelope of Phagocytosed Bacteria Allowing Antimicrobial Effectors Access to Intracellular Targets.

Bai F, McCormack RM, Hower S, Plano GV, Lichtenheld MG, Munson GP.

J Immunol. 2018 Nov 1;201(9):2710-2720. doi: 10.4049/jimmunol.1800365. Epub 2018 Sep 24.

2.

Perforin-2 is essential for intracellular defense of parenchymal cells and phagocytes against pathogenic bacteria.

McCormack RM, de Armas LR, Shiratsuchi M, Fiorentino DG, Olsson ML, Lichtenheld MG, Morales A, Lyapichev K, Gonzalez LE, Strbo N, Sukumar N, Stojadinovic O, Plano GV, Munson GP, Tomic-Canic M, Kirsner RS, Russell DG, Podack ER.

Elife. 2015 Sep 24;4. pii: e06508. doi: 10.7554/eLife.06508.

3.

Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.

Díaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ, Lichtenheld MG.

Immunol Res. 2013 Dec;57(1-3):23-33. doi: 10.1007/s12026-013-8456-1.

PMID:
24218360
4.

Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.

Díaz-Montero CM, Naga O, Zidan AA, Salem ML, Pallin M, Parmigiani A, Walker G, Wieder E, Komanduri K, Cole DJ, Montero AJ, Lichtenheld MG.

Am J Cancer Res. 2011 Aug 30;1(7):882-96.

5.

Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells.

Parmigiani A, Pallin MF, Schmidtmayerova H, Lichtenheld MG, Pahwa S.

Hum Immunol. 2011 Feb;72(2):115-23. doi: 10.1016/j.humimm.2010.10.015. Epub 2010 Oct 25.

6.

The transcriptional control of the perforin locus.

Pipkin ME, Rao A, Lichtenheld MG.

Immunol Rev. 2010 May;235(1):55-72. doi: 10.1111/j.0105-2896.2010.00905.x. Review.

7.

Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells.

Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A.

Immunity. 2010 Jan 29;32(1):79-90. doi: 10.1016/j.immuni.2009.11.012. Epub 2010 Jan 21.

8.

Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs.

Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A.

J Exp Med. 2009 Jan 16;206(1):51-9. doi: 10.1084/jem.20081242. Epub 2009 Jan 12.

9.

HIV Nef enhances Tat-mediated viral transcription through a hnRNP-K-nucleated signaling complex.

Wolf D, Witte V, Clark P, Blume K, Lichtenheld MG, Baur AS.

Cell Host Microbe. 2008 Oct 16;4(4):398-408. doi: 10.1016/j.chom.2008.08.013.

10.

Chromosome transfer activates and delineates a locus control region for perforin.

Pipkin ME, Ljutic B, Cruz-Guilloty F, Nouzova M, Rao A, Zúñiga-Pflücker JC, Lichtenheld MG.

Immunity. 2007 Jan;26(1):29-41. Epub 2007 Jan 11.

11.

Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV).

White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG, Pahwa RN, Pahwa S.

Blood. 2007 May 1;109(9):3873-80. Epub 2006 Dec 27.

12.
13.

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS, Beaupre DM.

Clin Cancer Res. 2005 Aug 15;11(16):6057-64.

14.

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM.

Blood. 2005 Jun 15;105(12):4759-66. Epub 2005 Feb 22.

15.

R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.

Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG.

Mol Cancer Ther. 2004 Feb;3(2):179-86.

16.

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.

Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH, Lichtenheld MG.

Leuk Lymphoma. 2003 Dec;44(12):2123-34.

PMID:
14959858
17.

A role for NF-kappa B activation in perforin expression of NK cells upon IL-2 receptor signaling.

Zhou J, Zhang J, Lichtenheld MG, Meadows GG.

J Immunol. 2002 Aug 1;169(3):1319-25.

18.
20.

Potent inhibition of CTLA-4 expression by an anti-CTLA-4 ribozyme.

Cepero E, Hnatyszyn HJ, Kraus G, Lichtenheld MG.

Biochem Biophys Res Commun. 1998 Jun 29;247(3):838-43.

PMID:
9647780
21.

Non-killer cell-specific transcription factors silence the perforin promoter.

Zhang Y, Lichtenheld MG.

J Immunol. 1997 Feb 15;158(4):1734-41.

PMID:
9029110
22.

Transgenic control of perforin gene expression. Functional evidence for two separate control regions.

Lichtenheld MG, Podack ER, Levy RB.

J Immunol. 1995 Mar 1;154(5):2153-63.

PMID:
7868890
24.
25.

Perforin and granzyme B as markers for acute rejection in heart transplantation.

Clément MV, Haddad P, Soulié A, Benvenuti C, Lichtenheld MG, Podack ER, Sigaux N, Sasportes M.

Int Immunol. 1991 Nov;3(11):1175-81.

PMID:
1760412
26.

A central role of perforin in cytolysis?

Podack ER, Hengartner H, Lichtenheld MG.

Annu Rev Immunol. 1991;9:129-57. Review.

PMID:
1910674
27.
28.

Cytolysis by Ca-permeable transmembrane channels. Pore formation causes extensive DNA degradation and cell lysis.

Hameed A, Olsen KJ, Lee MK, Lichtenheld MG, Podack ER.

J Exp Med. 1989 Mar 1;169(3):765-77.

29.

Structure and function of human perforin.

Lichtenheld MG, Olsen KJ, Lu P, Lowrey DM, Hameed A, Hengartner H, Podack ER.

Nature. 1988 Sep 29;335(6189):448-51.

PMID:
3419519

Supplemental Content

Loading ...
Support Center